Swiss firm Helsinn opens new $16.7 million R&D center in Ireland
Independent Swiss pharmaceutical group Helsinn last week officially opened its new 'center of excellence' for R&D, in Mulhuddar, Co Dublin, Ireland, which involved an investment of 13 million euros ($16.7 million), and was supported by the Irish Government through IDA Ireland.
The center, which will play a significant role in Helsinn's pipeline of new products including the NK-1 inhibitor netupitant for the treatment of emesis due to chemotherapy, and the novel ghrelin analogue anamorelin for the treatment of cachexia. The investment is expected to create up to 10 high-value research positions over the next few years.
Helsinn announced its plans to establish the facility last year (The Pharma Letter April 9, 2009), and following a successful construction phase the plant is now ready to commence operations. The center will be responsible for R&D for oral solid dosage formulations at the company's Helsinn Birex Pharmaceuticals, which it acquired in 1990 and which currently produces a range of drug products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze